Marine-Derived Bioactive Compounds for Neuroprotection

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 693

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy
Interests: neurocognitive disorders; gelatinase b; matrix metalloproteinases; antioxidant natural compounds; glial culture models; adjuvant therapies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy
Interests: neurological diseases; inflammation; oxidative stress; antioxidant compounds; matrix metalloproteinases; theranostic application; nanotechnologies

Special Issue Information

Dear Colleagues,

Marine organisms are recognized as a rich source of bioactive compounds with uncommon and unique chemical features that are not found in the terrestrial environment. These bioactive compounds have demonstrated potential for use in medical applications, exhibiting antioxidant, immunomodulatory, anti-inflammatory and anti-proliferative properties. Thus, they represent a potential source of novel drugs that can effectively act on molecular targets in various diseases, including neuroinflammatory and neurodegenerative disorders.

Currently, over a hundred natural products with significant neuroprotective activity have been isolated from aqueous or organic extracts of marine organisms and tested as potential drugs. The growing interest in exploring the marine environment for compounds with significant pharmacological potential represents a promising strategy and emerging trend for modern medicine. We invite scientists to submit reviews and original research articles that analyze the chemical and biological properties of marine natural products, highlighting their applications for the development on new neuroprotective drugs for the treatment of various central nervous system (CNS) diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other neurological diseases. The application of innovative scientific approaches in the extraction, characterization and testing of novel marine antiviral compounds is also welcome.

Dr. Grazia Maria Liuzzi
Dr. Tiziana Latronico
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine biocompounds
  • neuroprotection
  • neurodegeneration
  • neuroinflammation
  • central nervous system
  • Alzheimer’s disease
  • Parkinson’s disease
  • multiple sclerosis
  • antioxidant compounds

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

26 pages, 8897 KiB  
Article
Epicoccin A Ameliorates PD-like Symptoms in Zebrafish: Enhancement of PINK1/Parkin-Dependent Mitophagy and Inhibition of Excessive Oxidative Stress
by Haicheng Ye, Dan Li, Lei Zhang, Yufei Wang, Cong Wang, Meng Jin, Houwen Lin, Peihai Li, Chen Sun and Ning Li
Mar. Drugs 2025, 23(4), 175; https://doi.org/10.3390/md23040175 - 17 Apr 2025
Viewed by 543
Abstract
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, yet effective agents for its prevention and therapy remain highly limited. Epicoccin A, a significant secondary metabolite from Exserohilum sp., demonstrates various biological activities; however, its neuroprotective effects have not been elucidated. Here, [...] Read more.
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, yet effective agents for its prevention and therapy remain highly limited. Epicoccin A, a significant secondary metabolite from Exserohilum sp., demonstrates various biological activities; however, its neuroprotective effects have not been elucidated. Here, we investigated the therapeutic potential of epicoccin A for PD by evaluating its impact on neural phenotype, reactive oxygen species (ROS) generation, and locomotor activity in PD-like zebrafish. Transcriptomic analysis and molecular docking were conducted, with key gene expressions further verified using real-time qPCR. As a result, epicoccin A notably mitigated dopaminergic neuron loss, neural vasculature deficiency, nervous system injury, ROS accumulation, locomotor impairments, and abnormal expressions of hallmark genes associated with PD and oxidative stress. Underlying mechanism investigation indicated epicoccin A may alleviate PD-like symptoms by activating PINK1/Parkin-dependent mitophagy, as evidenced by the reversal of aberrant gene expressions related to the pink1/parkin pathway and its upstream mTOR/FoxO pathway following epicoccin A co-treatments. This finding was further confirmed by the robust interactions between epicoccin A and these mitophagy regulators. Our results suggest that epicoccin A relieves PD symptoms by activating pink1/parkin-dependent mitophagy and inhibiting excessive oxidative stress, highlighting its potential as a therapeutic approach for PD. Full article
(This article belongs to the Special Issue Marine-Derived Bioactive Compounds for Neuroprotection)
Show Figures

Figure 1

Back to TopTop